News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Merck & Co., Inc. Announces Completion of Acquisition Of Sirna Therapeutics, Inc.
December 29, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK) today announced that it has successfully completed the acquisition of Sirna Therapeutics, Inc. (NASDAQ: RNAI) in a cash transaction which closed in the fourth quarter of 2006.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Cancer
Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial
November 20, 2026
·
3 min read
·
Gabrielle Masson
Earnings
Novartis projects slowed growth, pins hopes on billions in pipeline potential
November 19, 2026
·
3 min read
·
Annalee Armstrong
Licensing
AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal
November 19, 2026
·
1 min read
·
Annalee Armstrong
Drug Development
Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
November 18, 2026
·
2 min read
·
Gabrielle Masson